Joannidis M, Rauchenzauner M, Leiner B, Rosenkranz A, Ebenbichler C F, Laimer M, Tatarczyk T, Meusburger E, Mayer G
Division of General Internal Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria.
Eur J Clin Nutr. 2008 Jun;62(6):789-95. doi: 10.1038/sj.ejcn.1602777. Epub 2007 May 16.
Evaluation of the influence of intradialytic parenteral nutrition (IDPN) in patients suffering from Malnutrition-Inflammation Complex Syndrome (MICS) on nutritional status, inflammation, adipocytokines and serum lipids.
Six patients with MICS were assigned to IDPN, whereas six patients matched for age, sex, body mass index (BMI) and co-morbidity without malnutrition served as controls. Patients were recruited from Outpatient Dialysis Unit, Medical University Innsbruck and from Dialysis Unit, Hospital Feldkirch.
In all patients with IDPN, dry body weight increased during the interventional period whereas body weight remained stable in patients without IDPN. Tumor necrosis factor (TNF)-alpha levels were higher in patients with MICS compared with controls at all time points. Total cholesterol, LDL- and HDL-levels significantly increased during dialysis at all time points in controls but not in patients with MICS. Albumin, C-reactive protein, interleukin-6 (IL-6), soluble interleukin-2 receptor (sIL-2R) and adipocytokines did not differ between patients and controls during the study period.
IDPN in patients with MICS increases body weight despite not influencing inflammatory status. Furthermore, IDPN does not induce a pro-atherogenic lipid composition enhancing the risk for atherosclerosis. Thus, IDPN is a safe and effective treatment of malnutrition in patients with MICS.
评估接受透析期间胃肠外营养(IDPN)的营养不良-炎症复合综合征(MICS)患者的营养状况、炎症反应、脂肪细胞因子和血脂受到的影响。
6例MICS患者接受IDPN治疗,另外6例年龄、性别、体重指数(BMI)和合并症匹配但无营养不良的患者作为对照。患者招募自因斯布鲁克医科大学门诊透析科和费尔德基希医院透析科。
在所有接受IDPN治疗的患者中,干体重在干预期间增加,而未接受IDPN治疗的患者体重保持稳定。在所有时间点,MICS患者的肿瘤坏死因子(TNF)-α水平均高于对照组。对照组在透析期间所有时间点的总胆固醇、低密度脂蛋白和高密度脂蛋白水平均显著升高,而MICS患者则不然。在研究期间,患者和对照组之间的白蛋白、C反应蛋白、白细胞介素-6(IL-6)、可溶性白细胞介素-2受体(sIL-2R)和脂肪细胞因子无差异。
MICS患者接受IDPN治疗可增加体重,尽管不影响炎症状态。此外,IDPN不会诱导促动脉粥样硬化的脂质组成增加动脉粥样硬化风险。因此,IDPN是治疗MICS患者营养不良的一种安全有效的方法。